![](/images/graphics-bg.png)
Maternal LopinavirRitonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir
Joint Authors
Davies, Jill
McFarland, Elizabeth J.
Smith, Christiana
Forster, Jeri E.
Pappas, Jennifer
Kinzie, Kay
Barr, Emily
Paul, Suzanne
Levin, Myron J.
Weinberg, Adriana
Source
Infectious Diseases in Obstetrics and Gynecology
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-04-04
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Abstract EN
Combination antiretroviral therapy (cART) is successfully used for prevention of perinatal HIV transmission.
To investigate safety, we compared adverse events (AE) among infants exposed to different maternal cART regimens.
We reviewed 158 HIV-uninfected infants born between 1997 and 2009, using logistic regression to model grade ≥1 AE and grade ≥3 AE as a function of maternal cART and confounding variables (preterm, C-section, illicit drug use, race, ethnicity, infant antiretrovirals, and maternal viremia).
Frequently used cART regimens included zidovudine (63%), lamivudine (80%), ritonavir-boosted lopinavir (37%), nelfinavir (26%), and atazanavir (10%).
At birth, anemia occurred in 13/140 infants (9%), neutropenia in 27/107 (25%), thrombocytopenia in 5/133 (4%), and liver enzyme elevation in 21/130 (16%).
Corresponding rates of AE at 4 weeks were 59/141 (42%), 54/130 (42%), 3/137 (2%), and 3/104 (3%), respectively.
Serious AE (grade ≥ 3) exceeded 2% only for neutropenia (13% at birth; 9% at 4 weeks).
Compared with infants exposed to maternal lopinavir/ritonavir, infants exposed to nelfinavir and atazanavir had a 5-fold and 4-fold higher incidence of AE at birth, respectively.
In conclusion, hematologic and hepatic AE were frequent, but rarely serious.
In this predominantly protease inhibitor-treated population, lopinavir/ritonavir was associated with the lowest rate of infant AE.
American Psychological Association (APA)
Smith, Christiana& Weinberg, Adriana& Forster, Jeri E.& Levin, Myron J.& Davies, Jill& Pappas, Jennifer…[et al.]. 2016. Maternal LopinavirRitonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infectious Diseases in Obstetrics and Gynecology،Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1104881
Modern Language Association (MLA)
Smith, Christiana…[et al.]. Maternal LopinavirRitonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infectious Diseases in Obstetrics and Gynecology No. 2016 (2016), pp.1-9.
https://search.emarefa.net/detail/BIM-1104881
American Medical Association (AMA)
Smith, Christiana& Weinberg, Adriana& Forster, Jeri E.& Levin, Myron J.& Davies, Jill& Pappas, Jennifer…[et al.]. Maternal LopinavirRitonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infectious Diseases in Obstetrics and Gynecology. 2016. Vol. 2016, no. 2016, pp.1-9.
https://search.emarefa.net/detail/BIM-1104881
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1104881